公开(公告)号：US11083785B2

公开(公告)日：2021-08-10

申请号：US15776452

申请日：2016-11-17

Applicant: INNATE PHARMA

Inventor： Stephanie Cornen ,  Laurent Gauthier ,  Benjamin Rossi ,  Nicolai Wagtmann

IPC: C07K14/705 ,  A61K39/00 ,  C07K16/28 ,  A61P35/00

Abstract: This disclosure relates to agents that bind and neutralize the inhibitory activity of Siglec-10 in lymphocytes, notably by inhibiting the binding of Siglec-10 to its sialic acid ligands on target cells, notably tumor cells. Such agents can be used for the treatment of cancers.

公开(公告)号：US11001629B2

公开(公告)日：2021-05-11

申请号：US16066688

申请日：2016-12-20

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: C07K16/28 ,  C07K16/46

Abstract: NKp-46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US10577419B2

公开(公告)日：2020-03-03

申请号：US14662349

申请日：2015-03-19

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Simon Kollnberger ,  Benjamin Rossi ,  Hélène Sicard ,  Carine Paturel ,  Stéphanie Cornen ,  Stéphanie Zerbib

IPC: C07K16/28 ,  G01N33/569 ,  A61K39/00

Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

公开(公告)号：US10280222B2

公开(公告)日：2019-05-07

申请号：US15125216

申请日：2015-03-12

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nicolas Schneider

IPC: C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K39/00 ,  A61K9/00

Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.

公开(公告)号：US10246510B2

公开(公告)日：2019-04-02

申请号：US14429416

申请日：2013-09-17

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Benjamin Rossi ,  Hélène Sicard ,  Carine Paturel

IPC: C07K16/28 ,  G01N33/569 ,  A61K47/68 ,  A61K39/00

Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

公开(公告)号：US20190055315A1

公开(公告)日：2019-02-21

申请号：US16173150

申请日：2018-10-29

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: C07K16/28

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US10113003B2

公开(公告)日：2018-10-30

申请号：US15190337

申请日：2016-06-23

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: A61K39/00 ,  C07K16/28

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US09828427B2

公开(公告)日：2017-11-28

申请号：US14924786

申请日：2015-10-28

Applicant: INNATE PHARMA

Inventor： Nicolas Anfossi ,  Laurent Gauthier ,  Yannis Morel ,  Alessandro Moretta ,  Silvia Parolini ,  Benjamin Rossi

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K45/06

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732

Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.

公开(公告)号：US09717803B2

公开(公告)日：2017-08-01

申请号：US13725382

申请日：2012-12-21

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Delphine Bregeon ,  Patrick Dennler ,  Christian Belmant ,  Eliane Fischer ,  Laurent Gauthier ,  Francois Romagné ,  Roger Schibli

IPC: A61K47/48 ,  C07K16/00 ,  C07K16/30 ,  C07K19/00 ,  A61K31/5517 ,  C07C217/08 ,  C07C223/02 ,  C07C229/26 ,  C07C233/62 ,  C07C247/04 ,  C07C323/12 ,  C07C323/60 ,  C07D225/08 ,  C07D257/08 ,  C07D277/06 ,  C07F9/50 ,  C12N9/10 ,  C12P21/00 ,  G01N33/68

CPC classification number: A61K47/6803 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6807 ,  A61K47/6813 ,  A61K47/6817 ,  A61K47/6865 ,  A61K47/6871 ,  C07C217/08 ,  C07C223/02 ,  C07C229/26 ,  C07C233/62 ,  C07C247/04 ,  C07C323/12 ,  C07C323/60 ,  C07D225/08 ,  C07D257/08 ,  C07D277/06 ,  C07F9/5022 ,  C07K16/00 ,  C07K19/00 ,  C07K2317/40 ,  C12N9/1044 ,  C12P21/005 ,  G01N33/6854

Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

公开(公告)号：US20160331842A1

公开(公告)日：2016-11-17

申请号：US15214331

申请日：2016-07-19

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Delphine Bregeon ,  Patrick Dennler ,  Christian Belmant ,  Laurent Gauthier ,  François Romagne ,  Eliane Fischer ,  Roger Schibli

IPC: A61K47/48 ,  C07K16/30 ,  A61K31/5517

CPC classification number: A61K47/48569 ,  A61K31/5517 ,  A61K47/6801 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6889 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/40

Abstract: The present application relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.